

PROGENICS PHARMACEUTICALS INC
Form SC 13G/A
February 14, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 15)*

PROGENICS PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK, par value \$.0013

(Title of Class of Securities)

743187106

(CUSIP Number)

December 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Page 1

CUSIP No. 743187106

- 1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Tudor Investment Corporation

22-2514825

- 2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----

(b) X

- 3) SEC Use Only

- 4) Citizenship or Place of Organization Delaware

(5) Sole Voting Power 0

Number of Shares Beneficially (6) Shared Voting Power 2,342,388
Owned by Each
Reporting Person

With (7) Sole Dispositive Power 0

(8) Shared Dispositive Power 2,342,388

- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,342,388

- 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) -----

- 11) Percent of Class Represented by Amount in Row 9 3.8%

- 12) Type of Reporting Person (See Instructions) CO

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Page 2

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Tudor Group Holdings LLC

13-3862746

2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a) -----

(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization Delaware

	(5)	Sole Voting Power	0
Number of Shares			
Beneficially	(6)	Shared Voting Power	0
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	0
With			
	(8)	Shared Dispositive Power	0

9) Aggregate Amount Beneficially Owned by Each Reporting Person 0

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) -----

11) Percent of Class Represented by Amount in Row 9 0%

12) Type of Reporting Person (See Instructions) 00

Page 3

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Paul Tudor Jones, II

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization USA

	(5)	Sole Voting Power	546,125
Number of Shares			
Beneficially	(6)	Shared Voting Power	2,342,388
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	546,125
With			
	(8)	Shared Dispositive Power	2,342,388

9) Aggregate Amount Beneficially Owned by Each Reporting Person
2,888,513

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11) Percent of Class Represented by Amount in Row 9 4.7%

12) Type of Reporting Person (See Instructions) IN

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Mark F. Dalton

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----
(b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization USA

	(5)	Sole Voting Power	107,500
Number of Shares			
Beneficially	(6)	Shared Voting Power	2,342,388
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	107,500
With			
	(8)	Shared Dispositive Power	2,342,388

9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,449,888

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11) Percent of Class Represented by Amount in Row 9 4.0%

12) Type of Reporting Person (See Instructions) IN

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
 S.S. or I.R.S. Identification No. of Above Person

 The Tudor BVI Global Portfolio L.P. (f/k/a The Tudor BVI Global
 Portfolio Ltd.)

 98-0223576

2) Check the Appropriate Box if a Member of a Group (See Instructions)
 (a) -----
 (b) X

3) SEC Use Only -----

4) Citizenship or Place of Organization Cayman Islands

	(5)	Sole Voting Power	0
Number of Shares			
Beneficially	(6)	Shared Voting Power	1,613,905
Owned by Each			
Reporting Person			
With	(7)	Sole Dispositive Power	0
	(8)	Shared Dispositive Power	1,613,905

9) Aggregate Amount Beneficially Owned by Each
 Reporting Person 1,613,905

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
 (See Instructions) -----

11) Percent of Class Represented by Amount in Row 9 2.7%

12) Type of Reporting Person (See Instructions) PN

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
 S.S. or I.R.S. Identification No. of Above Person

Tudor Global Fund L.P.

98-0677065

2) Check the Appropriate Box if a Member of a Group (See Instructions)
 (a) -----

(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Cayman Islands

(5) Sole Voting Power 0

Number of Shares Beneficially Owned by Each Reporting Person With
 (6) Shared Voting Power 440,670

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 440,670

9) Aggregate Amount Beneficially Owned by Each Reporting Person 440,670

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11) Percent of Class Represented by Amount in Row 9 0.7%

12) Type of Reporting Person (See Instructions) PN

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 743187106

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Tudor Proprietary Trading, L.L.C.

13-3720063

2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) -----

(b) X

3) SEC Use Only

4) Citizenship or Place of Organization Delaware

(5) Sole Voting Power 0

Number of Shares Beneficially Owned by Each Reporting Person With
(6) Shared Voting Power 0

(7) Sole Dispositive Power 0

(8) Shared Dispositive Power 0

9) Aggregate Amount Beneficially Owned by Each Reporting Person 0

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11) Percent of Class Represented by Amount in Row 9 0%

12) Type of Reporting Person (See Instructions) OO

CUSIP No. 743187106

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

1) Names of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

Tudor Global Trading LLC

13-3862744

2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a) _____

(b) X

3) SEC Use Only _____

4) Citizenship or Place of Organization Delaware

	(5)	Sole Voting Power	0
Number of Shares			
Beneficially	(6)	Shared Voting Power	0
Owned by Each			
Reporting Person	(7)	Sole Dispositive Power	0
With			
	(8)	Shared Dispositive Power	0

9) Aggregate Amount Beneficially Owned by Each Reporting Person 0

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11) Percent of Class Represented by Amount in Row 9 0%

12) Type of Reporting Person (See Instructions) 00

Item 1(a). Name of Issuer:

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Progenics Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

777 Old Saw Mill River Road
Tarrytown, NY 10591

Item 2(a). Name of Person Filing:

Tudor Investment Corporation ("TIC")
Tudor Group Holdings LLC ("TGH")
Paul Tudor Jones, II
Mark F. Dalton
The Tudor BVI Global Portfolio L.P. ("Tudor BVI")
Tudor Global Fund L.P. ("TGF")
Tudor Proprietary Trading, L.L.C. ("TPT")
Tudor Global Trading LLC ("TGT")

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business office of each of TIC, TGH, TPT, TGF and TGT is:

1275 King Street
Greenwich, CT 06831

The principal business office of each of Messrs. Jones and Dalton is:

c/o Tudor Investment Corporation
1275 King Street
Greenwich, CT 06831

The principal business office of Tudor BVI is:

c/o CITCO
Kaya Flamboyan 9
Curacao, Netherlands Antilles

Item 2(c). Citizenship:

TIC is a Delaware corporation
Tudor BVI and TGF are limited partnerships organized under the laws
of the Cayman Islands
Messrs. Jones and Dalton are citizens of the United States
TGH, TPT and TGT are Delaware limited liability companies

Item 2(d). Title of Class of Securities:

Page 10

Common Stock, par value \$0.0013

Item 2(e). CUSIP Number:

743187106

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b),

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E).
- (f) An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) A non-U.S. institution in accordance with ss. 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with ss. 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with ss. 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____

Item 4. Ownership (as of December 31, 2013).

- (a) Amount Beneficially Owned: See Item 9 of cover pages
- (b) Percent of Class: See Item 11 of cover pages
- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote
See Item 5 of cover pages

 - (ii) shared power to vote or to direct the vote
See Item 6 of cover pages

- (iii) sole power to dispose or to direct the disposition of
See Item 7 of cover pages

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

(iv) shared power to dispose or to direct the disposition of
See Item 8 of cover pages

The shares of common stock ("Shares") reported herein as beneficially owned by TIC, TGH, Mr. Jones and/or Mr. Dalton include shares owned directly by Tudor BVI (1,613,905 Shares), and/or TGF (440,670 Shares).

Because TIC provides investment advisory services to each of Tudor BVI and TGF and acts as general partner of TGF, TIC may be deemed to beneficially own the Shares owned by Tudor BVI and TGF. TIC expressly disclaims beneficial ownership of such Shares. TGH holds a majority of the equity interests of TGT and indirectly holds a majority of the membership interests of TPT. TGH expressly disclaims beneficial ownership of the Shares beneficially owned by each of such entities. Mr. Jones is the Co-Chairman and principal equity owner of TIC and TGH. Mr. Jones expressly disclaims beneficial ownership of the Shares beneficially owned, or deemed beneficially owned, by such entities. Mr. Dalton is (i) the Co-Chairman, Chief Executive Officer, and an equity owner of TIC and (ii) the Co-Chairman, Chief Executive Officer, and an equity owner of TGH. Mr. Dalton expressly disclaims beneficial ownership of the Shares beneficially owned, or deemed beneficially owned, by such entities.

The Shares reported herein under Items 5 and 7 of Mr. Jones' cover page include 4,600 Shares held directly by Mr. Jones' individual retirement account.

The Shares reported herein under Items 5 and 7 of Mr. Dalton's cover page include 70,000 immediately exercisable options (the "Options"). Further, the Shares reported herein under Items 5 and 7 of Mr. Dalton's cover page include 37,500 of the Shares.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parents Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

See cover pages

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 13

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2014

TUDOR INVESTMENT CORPORATION

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel

TUDOR GROUP HOLDINGS LLC

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel

/s/ Paul Tudor Jones, II

Paul Tudor Jones, II

/s/ Mark F. Dalton

Mark F. Dalton

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

THE TUDOR BVI GLOBAL PORTFOLIO L.P.

By: Tudor BVI GP Ltd.
Its: General Partner

By: Tudor Investment Corporation,
Trading Advisor

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel

TUDOR GLOBAL FUND L.P.

By: Tudor Investment Corporation,
Its: General Partner

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel

TUDOR PROPRIETARY TRADING, L.L.C.

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel

TUDOR GLOBAL TRADING LLC

By: /s/ Stephen N. Waldman

Stephen N. Waldman
Managing Director and Deputy
General Counsel